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Abstract
Therapeutic treatments based on the injection of living cells are in clinical use and preclinical
development for diseases ranging from cancer to cardiovascular disease to diabetes. To enhance
the function of therapeutic cells, a variety of chemical and materials science strategies are being
developed that engineer the surface of therapeutic cells with new molecules, artificial receptors,
and multifunctional nanomaterials, synthetically endowing donor cells with new properties and
functions. These approaches offer a powerful complement to traditional genetic engineering
strategies for enhancing the function of living cells.
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Introduction
Cell therapies are clinical procedures involving the direct transplantation, injection, or
infusion of live cells to treat disease. These donor cells can be autologous (from the same
patient) or allogeneic (from an unrelated donor). Cell therapy is a rapidly expanding field in
translational medicine, encompassing both well-established procedures as well as advanced
therapies still in early preclinical testing. While hematopoietic stem cell transplants (bone
marrow transplants) have essentially become standard-of-care for the treatment of leukemia
and related bone and blood cancers with nearly 40,000 procedures per year worldwide[1], a
plethora of non-hematopoietic adult stem cell therapies are also undergoing clinical
evaluation. In particular, mesenchymal stem cells (MSCs) have emerged as cornerstones of
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regenerative medicine strategies, based on their diverse spectrum of differentiation into
cartilage, bone, cardiomyocytes or neurons, and the ease of culturing quantities appropriate
for clinical applications[2–4]. Moreover, MSCs can suppress lymphocyte proliferation, which
is being explored clinically to treat T cell-dependent pathologies, such as multiple
sclerosis[5], amylotrophic lateral sclerosis[6], transplant rejection[7] or acute graft-versus-host
disease[8]. Beyond stem cells, a manifold of differentiated functional cells are clinically
exploited. For example, a cell technology poised to have a major impact on the treatment of
end-stage heart failure is the intra-coronary infusion of skeletal myoblasts[9]. A related
strategy is employed when infusing functional beta-islets cells into the portal vein of type I
diabetic patients to restore natural insulin production, thereby eliminating the need for
repeated insulin injections[10]. Autologous ex-vivo expanded tumor- or virus-specific
effector T lymphocytes have shown tremendous therapeutic potential when adoptively
transferred into patients with advanced malignancies[11] or chronic infections, such as
HIV[12]. Also in the field of cellular tumor immunotherapy, injections of autologous ex-vivo
matured dendritic cells loaded with tumor antigen represent a promising treatment modality
to stimulate anti-tumor immunity[13]. Earlier this year, this methodology received FDA
approval as the first cellular immunotherapy product (Provenge®) for the treatment of
metastatic cancer[13]. Ultimately, the current cell therapy armamentarium will be critically
expanded by the addition of induced pluripotent stem cells (iPSCs), which not only offer
exciting prospects for regenerative medicine, but also the correction of genetic defects, such
as beta-thalassemia or sickle cell anemia, at the stem cell level[14,15]. Thus, the field of cell
therapy includes diverse therapeutic applications employing donor cells ranging from the
earliest progenitor cells to terminally differentiated tissue cells.
The efficacy of cell therapies hinges on appropriate control of the fate and function of the
therapeutic cells, and engineering donor cells for enhanced survival, proliferation, or
differentiated function is a topic of central interest. Cell function has traditionally been
engineered in three distinct ways, either by (1) preconditioning cells for enhanced in vivo
effector function, self renewal or longevity by ex vivo exposure to soluble cytokines[16–18],
pharmacological agents[19,20]or stimulatory ligands[21,22] (2) providing supporting adjuvant
drug treatment by systemic bolus injections in parallel with cell therapies[23,24] ((modulating
cell function via exogenous, systemic external cues) or (3) by genetic engineering,
employing the tools of molecular biology to modify the genetic programming of cells[25,26].
Recently, a fourth approach has begun to gain attention, based on using synthetic materials
or chemical biology approaches to alter cell surfaces. This complementary strategy lies
somewhere between the two extremes of chemotherapy and genetic engineering, allowing
exogenous cues to be provided to cells in a novel manner by directly remodeling the cell
itself, employing the tools of chemistry and materials science in addition to molecular
biology. Success in this arena depends on the recognition of the plasma membrane itself as a
complex nanostructured surface, composed of organized lipids, proteins, and polysaccharide
assemblies whose nanoscale organization can impact cell function. Synthetic nanomaterials
have a significant role to play in cell surface engineering, due to their unique properties and
ability to provide functionality beyond that achievable by single molecules. In this review,
we will first summarize key methodologies used to manipulate the surface of living
mammalian cells with synthetic material. We will then discuss the main challenges to
overcome to stably modify cell surfaces and we will highlight how these cell modifications
can be applied to enhance the therapeutic potential of cell products in clinic. Finally, we will
outline future trends and perspectives of this relatively new and fast-developing discipline.
Motivations for exploiting cell surface bioengineering in cell therapy
Rapid progress in basic biology has defined a host of signaling pathways that could be
modulated to endow therapeutic cells with enhanced functionality. The characterization of
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cell surface receptors, their respective ligands, and downstream signaling pathways that
integrate external cues to regulate cell survival, proliferation, and differentiation, have
provided motivation for the rational remodeling of cell surfaces for therapeutic purposes. In
addition, because the cell surface controls all interactions of the cell with its environment,
cell functions such as adhesion, migration, tissue homing, and cell-cell interactions can all
be redefined via engineering of the molecular landscape of the plasma membrane.
Genetic engineering is well established as a robust and highly versatile methodology for
introducing or knocking down specific surface proteins to modulate cell functionality[27,28].
However, technical challenges of efficient gene transfer, laborious gene transduction
protocols and the safety concerns of unintentionally activating oncogenes through the
random insertion of transgenes into the target cell genome hinder gene therapy in the clinical
setting[29]. Genetic cell engineering is further constrained by limits on the size of genes that
can be carried into cells using the most efficient current clinically-useful gene delivery
vehicles, recombinant viruses. Thus, it is technically challenging to engineer cells with
multiple genes[27]. Finally, gene therapy only allows cells to be engineered within the rule
set of cellular biochemistry, and cannot be used to modify cell surfaces with non-biological
therapeutic materials (e.g., non-biological small molecules, fluorescent tags, clinical
imaging contrast agents, reactive polymers, complex nanocarriers, etc.) or to introduce
biomolecules on the cell surface that do not have a biological mechanism for placement
there (e.g., DNA or RNA). These limitations have fueled interest in devising novel
bioconjugation, protein engineering, chemistry, and material science approaches with the
goal of rationally modifying the molecular landscape on the cell surface.
What are the goals of cell surface engineering? Key applications include engineering cell
adhesion[30] and in vivo cell migration by the introduction of exogenous targeting ligands
into the cell membrane[31–33] or by manipulating cell surface glycosylation[34,35]. Likewise,
stimulatory biomolecules or biological components that mimic a supportive
microenvironment can be surface-coupled to transplanted cells to enhance their longevity,
proliferative reserves and therapeutic potential[36]. Prolonged in vivo persistence and
functionality of grafted cells is of particular importance in cell xeno-transplants, which can
be rapidly destroyed by the recipient’s immune system[37]. To safeguard against immune
rejection during early cell engraftment, transplanted cells can be camouflaged by polymer
coatings[38]. Alternatively, the coupling of immune-inhibitory ligands or small molecules to
the surface of transplanted cells could be envisioned as a promising strategy to locally blunt
immune attacks. With next-generation biomaterials and synthetic nanocarriers emerging at
rapid pace, cell bioengineering methodologies are ultimately poised to extend far beyond
enhancing the efficacy of established cell-based therapies. One new area of intense research,
which is based on the necessity to deliver drugs in a more directed and controlled manner to
disease-relevant sites, is to decorate isolated cells, which display a defined in vivo migration
pattern, with synthetic drug nanocarriers. Following adoptive transfer, cells actively
transmigrate endothelial and stromal barriers and accumulate surface-attached cargo at
pathological sites[39,40]. This is in contrast to conventional static drug targeting ligands, like
antibodies, which rely on passive mechanisms, such as the enhanced permeation and
retention (EPR)[41] to cross vascular endothelium and initially accumulate near target cells.
As further outlined below, dynamic cell-nanoparticle hybrid vehicles could be applied to
deliver a wide range of therapeutic agents, including small molecules, siRNA, contrast
agents or vaccines to therapeutically desired anatomical compartments.
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Challenges of cell surface engineering
Criteria for developing clinically-viable cell surface bioengineering strategies
Any cell surface bioengineering strategy developed in a preclinical setting should ideally
meet several criteria to be of translational relevance for clinical cell therapy applications.
First, to avoid loss of cell viability, conventional bioconjugation/bioengineering-protocols
need to be carefully adapted for the purpose of engineering primary cells. Small changes in
pH or osmolarity, exposure of cells to organic solvents, heat, excessive agitation, or serum
starvation can have profound effects on cell viability and/or differentiated function. In most
instances, surface bioengineering should further minimize alterations in membrane fluidity,
i.e. the viscosity of the lipid bilayer, or changes to the bending elasticity of the cell
membrane, since cell functions, such as adhesion, migration, proliferation and cell signaling
critically depend on these physical parameters[42–44]. Considering the complexity and
myriad functions of cell membrane surface proteins, glycolipids and polysaccharides, the
main challenge of cell surface engineering remains to rationally modify select cell-surface
molecules without physically blocking or functionally compromising others.
Cell membrane turnover and internalization as limiting factors
Cell surface engineering is complicated by the fact that the plasma membrane is not a static
structure, but rather is always in a dynamic state[45]. In addition to constant redistribution
and compartmentation in the lateral plane of the cell membrane, both lipid and protein
components of the plasma membrane are continuously internalized, degraded, and replaced
by de novo synthesis[46]. This is a highly selective process with specific turnover rates for
different proteins and lipids ranging from hours to several weeks[47]. Internalization of lipids
and protein from the cell surface occurs through processes of endocytosis, pinocytosis, or
phagocytosis. In endocytosis[48], binding of ligands to cell surface receptors triggers a
specific response where small pockets (e.g., ~50 nm in diameter) of the plasma membrane
around the engaged receptor invaginate and pinch off to form closed vesicles. These budded
vesicles are trafficked into the cell, and the internalized materials are sorted for intracellular
transport or recycling to the membrane. While endocytosis is cargo-specific, non-specific
uptake is dominated by pinocytosis[49]. This process involves continual invagination and
budding of vesicles from the cell surface, allowing fluid and extracellular material to enter
the cell. Conversely, intracellular transport vesicles fuse with the plasma membrane to
release proteins into the extracellular space during exocytosis. Endocytosis and pinocytosis
traffic small quantities of membrane and adjacent fluid into the cell. By contrast, large
membrane areas are internalized during phagocytosis, a process used by specialized cells
such as macrophages, neutrophils, and dendritic cells to remove pathogens, cell debris or
dying cells from the extracellular environment[50]. The dynamic nature of the cell surface is
a major challenge to cell surface engineering, which may lead to premature internalization
and ultimately degradation of surface modifications or cell-conjugated nanocarriers.
Therefore, numerous approaches, which are discussed in detail below, have been developed
to prolong retention of engineered membrane components on the surfaces of cells. In recent
years, significant progress has been made in understanding how the geometry and charge of
biomaterials, their surface chemistry, and the strategy chosen to hybridize biomaterials with
cell surfaces affect their internalization rate into cells.
Mechanical and biochemical challenges of the in vivo environment
The third key challenge to cell surface engineering is to introduce synthetic modifications
that are compatible with the complex mechanical and biochemical environment the cell is
exposed to in vivo. Following cell transplantation or adoptive transfer, cells will be exposed
to in vivo shear stress and hemodynamic forces, and circulating cells such as leukocytes or
stem cells undergo extensive reshaping during endothelial transmigration and migration
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through tissues[51,52]. Uncompromised elasticity is also prerequisite for a cell to repeatedly
squeeze through the dense network of fenestrated sinusoidal vessels in the spleen, which
efficiently filters damaged or aged cells from the blood circulation[53]. Once biomaterial-
modified cells come into contact with human blood, they are also exposed to soluble and
cellular blood components of the immune system and the blood coagulation cascade, which
may adversely affect in vivo cell persistence and therapeutic function[54,55]. For instance,
cell surface-conjugated particulate biomaterials become prone to phagocytosis by monocytes
and macrophages[56]. Immunogenic xenoproteins, such as streptavidin, a common linker for
bioconjugation, elicit neutralizing antibodies, which can opsonize and clear the engineered
therapeutic cell product. Aggregation of surface-engineered cells with blood platelets or the
activation of blood clotting factors could lead to thrombus formation and serious
complications[57,58]. In particular negatively charged materials, which to some extent mimic
extracellular matrix and bacterial lipopolysaccharides, could render intrinsically
athrombogenic cell surfaces thrombogenic and trigger vessel blockade[59].
Efficient “masking” of synthetic modifications on the cell surface from soluble and cellular
blood components can be achieved by covalent attachment of a reactive derivative of
polyethylene glycol (PEG)[60,61]. The concept of linking one or more highly flexible PEG
chains to small molecules, proteins, peptides or whole cells to prolong their body-residence
has reached widespread applications in modern pharmaceutical technology, which have been
reviewed extensively[62–64]. As a tool to safeguard modified cell surfaces from adsorption of
opsonic proteins or unspecific phagocytosis, PEGylation has been implemented in a variety
of protocols, detailed further below.
Cell surface engineering with exogenous materials
As described above, materials of interest for modifying the surface of cells range from
recombinant proteins to imaging agents to drug-loaded nanoparticles. The starting point for
any cell engineering endeavor is to determine how to interface the cell with these exogenous
materials, given the constraints to clinical cell engineering just discussed. Reflecting the
complex structure of the plasma membrane and its various constituents, a diverse toolbox of
bioengineering methodologies has been developed over recent years to rationally modify the
surface of therapeutic cells (Fig. 1). The strategy perhaps most straightforward, but which
provides the least control over the resulting cell surface remodeling, is chemical conjugation
of molecules or nanomaterial cargos to the cell via pre-existing functional groups on cell
surface proteins, polysaccharides, or lipids (Fig. 1a, b). Alternatively, cargo materials
conjugated with lipophilic molecules can spontaneously associate with the plasma
membrane via spontaneous insertion of these hydrophobic anchors into the bilayer, allowing
the membrane to be decorated with novel structures (Fig. 1c, d). Finally, cell surface
receptors can themselves act as binding sites to interface materials with the cell surface, by
building ligands for target receptors into the nanomaterials of interest for cell surface
engineering[65] (Fig. 1e). Utilization of antibodies, aptamers, or other engineered binding
molecules to attach nanomaterials to the cell surface is a variation on this approach, which in
theory could allow any desired molecule on the cell surface to serve as an anchor for
attachment of materials to the cell. Each of these approaches finds utility in different
situations.
Chemical/enzymatic cell surface modification exploiting functional groups or molecules
naturally present on the cell surface
Functional groups naturally present on the cell surface as part of proteins or carbohydrates
are appealing docking sites for the covalent conjugation of therapeutic materials to cells
since they do not require any chemical preconditioning of the cell. The most straightforward
approach involves direct chemical reaction of an amino (lysine – NH2) or thiol (cysteine –
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SH) group presented on a cell membrane protein with a compatible reactive group on
exogenous small molecules, proteins, polymers, or nanoparticles (Fig. 1a, b). This strategy is
exemplified by the direct coupling of succinmidyl ester-functionalized polyethylene glycol
(PEG) to cell surface amines of pancreatic islets to camouflage potentially immunogenic
surface antigens[66]. Using similar chemistry, Hsiao et al. attached amine-reactive ssDNA
conjugates to cells through reaction with cell-surface lysines as a method to array cells on
DNA-functionalized surfaces in defined patterns[67]. Biotinylation of cell surfaces is also
most commonly achieved through reaction of primary amine groups present on the cell
membrane with amine-reactive biotin, such as N-hydroxy-succinimide biotin derivatives;
once a cell is labeled with biotin, it can be readily functionalized with a wide range of
biotinylated molecules or particles through a streptavidin bridge[31,68,69] (Fig. 1b). To
reduce the number of incubation/washing steps protocols have been reported that either
genetically fuse streptavidin to recombinant proteins[70,71] or chemically pre-conjugate
streptavidin to nanoparticles before incubation with biotinylated cell surfaces[72]. A second
approach is to make use of free thiols present in cysteine residues of proteins on the surface
of mammalian cells. Reduced thiols at the cell surface play a role in protecting cell surfaces
against oxygen radicals[73–75] and fine tune cell signaling and differentiation[76,77]. Thiol-
reactive functional groups such as maleimide can thus be employed to link molecules or
nanoparticles to the surface of cells (Fig. 1a). Notably, it has been shown that lipid or
polymer particles in the 100–300 nm size range can be linked to cells via maleimide-thiol
conjugation to live cells without compromising cell function[36].
In addition to amino or thiol groups, aldehydes and ketones have been used successfully to
covalently attach surface-modifying molecules. The main drawback of using this approach,
however, is that these reactive groups must be generated through chemical or enzymatic
treatment of existing cell surface carbohydrates. For example, Yang and coworkers treated
macrophages with sodium periodate to generate aldehyde groups on sialic acid residues[78].
These aldehydes were in turn reacted with amino-derivatized PEG-quantum dots to form
transient Schiff base linkages. Finally, reduction with NaCNBH3 created a stable amine
bond. For a narrow range of applications, enzymatic transformation of existing cell surface
molecules to directly produce the desired modification is an efficient option. To this end,
McEver pioneered a simple method to improve HSC homing and engraftment by ex vivo
fucosylation of cord blood with guanosine diphosphate fucose and exogenous α1–3
fucosyltransferase to increase HSC tethering to P-selectin and E-selectin on activated
endothelium[79]. Building on this approach, Sackstein and co-workers fucosylated surface
CD44 on human MSCs to promote their adhesion with bone marrow vasculature following
intravenous administration[35,80]. This innovative tool to custom engineer therapeutically
desirable cell surface glycoforms will be discussed in more detail below.
Metabolic or genetic introduction of reactive functional groups on the cell surface
The concept of metabolically introducing chemical functional groups that are absent from
the native plasma membrane as molecular handles for remodeling the cell surface was
pioneered by Reutter and colleagues in 1992[81]. Their studies first demonstrated that
nonphysiological amino sugar analogues could be metabolically incorporated into
membrane glycoconjugates through natural carbohydrate biosynthetic pathways. In
particular, sialic acids are an appealing target of metabolic oligosaccharide engineering. As
the most abundant terminal components of membrane glycolipids, they are positioned on the
outer periphery of the cell and, therefore, situated in ideal proximity for subsequent
attachment of externally delivered reagents (Fig. 1f). In a series of studies, Bertozzi and
coworkers metabolically introduced ketone- or azide-groups into sialic acid[82–84], thereby
enabling surface conjugation of cells with various compounds[85,86] or in tissue engineering
applications to covalently attach cells to synthetic scaffolds decorated with complementary
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functional groups[87]. The same concept can be applied to metabolically install reactive thiol
groups into the outer periphery of the glycocalyx where they are most accessible to
maleimide-derivatized materials[88].
Genetic engineering can also be used to introduce “bio-orthogonal” reactive groups into cell
surface proteins, creating sites for selective modification of cells via a combination of
traditional molecular biology and exogenous materials science/chemical methods. For
example, Ting and colleagues developed a robust methodology to incorporate biotin groups
site-specifically into desired cell surface proteins, exploiting the Escherichia coli enzyme
biotin ligase (BirA)[89]: This enzyme biotinylates a lysine side chain within a 15-amino acid
acceptor peptide (AP) sequence. As an initial step of this strategy, the AP tag is genetically
fused to the N terminus or C terminus of a protein of interest. Following cell transfection,
BirA enzyme, which is added to the culture medium with biotin and ATP, biotinylates AP-
tags of surface-expressed proteins. These biotin groups can then be targeted with
streptavidin conjugates (Fig. 1g). BirA-catalyzed ligations also permit the derivatization of
membrane proteins with ketone groups, if ketone analogues of biotin are exogenously
supplied, which further extends the spectrum of possible conjugates[90]. In a variation of the
BirA ligation approach, a 22 amino acid peptide tag can be genetically engineered into
proteins, to serve as a substrate for enzymatic ligation of an unnatural alkyl azide substrate
by E. Coli lipoic acid ligase (LplA)[91]. Although these approaches require genetic
manipulation of the substrate cell, they allow the location and identity of the reactive site on
the cell surface (which protein, in what location) to be specified, providing greater control
over the nature of subsequent cell surface remodeling than linkages introduced through
naturally-occurring reactive groups described above.
Hydrophobic insertion into the cell membrane
Integral membrane proteins are anchored into the cell membrane through hydrophobic
residues in their transmembrane helices, which make complementary interactions with the
hydrophobic lipid bilayer[92]. This hydrophobic effect that governs the incorporation and
orientation transmembrane proteins can also be put to use for cell surface engineering. When
molecules or nanoparticles conjugated with an appropriate hydrophobic anchor are admixed
with cultured cells, the hydrophobic moiety can spontaneously insert into the lipid bilayer,
anchoring the conjugated cargo on the surface (Fig. 1c, d). One example of this general
approach, termed “protein painting” uses hydrophobic glycoinositol phospholipids (GPIs) to
anchor proteins to the outer cell membrane[93]. During physiological protein synthesis, GPIs
are attached post-translationally to the C-terminus of select proteins, which direct them into
lipid rafts of the outer cell surface membrane[94]. Recombinant GPI-anchored proteins form
micelles in solution and subsequently can be exogenously re-incorporated into the plasma
membrane of any target cell, where they retain their natural function[93,95]. Furthermore,
recombinant DNA technologies make it possible to introduce new properties into GPI-linked
proteins. For example, Nelson et al. genetically rendered the potent T cell activator
RANTES immune-inhibitory and introduced a GPI-anchored version of this construct into
the external membrane of endothelial cells to protect vasculature from acute immune
rejection in xenotransplanted organs[96]. To immobilize a wide range of therapeutically
relevant antibodies on cell surfaces, without the need to individually express them as GPI-
tagged fusion proteins, target cells can first be coated with chemically-palmitated protein A
or protein G (Fig. 1d)[97–99]. These proteins bind immunoglobulins through their Fc region
and anchor antibodies to cell membranes without compromising their affinity or
functionality. In theory, this method can be applied to any given protein by genetic fusion
with an Fc domain, as demonstrated by Tykocinski and coworkers[100]. Using a two-step
procedure, this group first precoated antigen presenting cells with palmitated protein A and
subsequently “painted” cells with costimulatory B7.1-Fcγ1 fusion protein.
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As a new group of therapeutics, “prosthetic” surface receptors that mimic the architecture or
function of physiological receptor proteins can be chemically synthesized[101]. These
compounds seamlessly incorporate into the surface membrane of cells and, for instance,
enable the delivery of cell-impermeable molecules. The Peterson group has synthesized a
range of cell surface receptor mimics composed of a ligand-binding small molecule or
peptide linked to an N-alkyl derivative of 3β-cholesterylamine, which acts as membrane
anchor[102,103]. In a related study, Bertozzi and coworkers functionalized synthetic
glycopolymers, designed to mimic cell surface mucins with a hydrophobic anchor.
Following incubation with live cells, these mucin-mimic polymers spontaneously
incorporated into the cell surface membrane and retained the ability to recognize glycan-
binding proteins[34].
An interesting alternative to unimolecular insertion of therapeutic proteins or molecules into
cell membranes was recently reported by Sarkar et al[104]. To surface-functionalize MSCs
with the targeting ligand sialyl Lewis X (SLeX), unilamellar lipid vesicles composed of
biotinylated lipid were fused with MSCs. Subsequently, biotinylated SLeX could be
immobilized on the cell surface through a biotin-streptavidin bridge.
Adsorption
The surface of mammalian cells carries a net negative charge, as a result of phosphate
groups of phospholipids, carboxylate groups on proteins, and sialic acids terminating
glycoproteins sugar chains[105]. The high ionic strength of physiological solutions makes
monovalent electrostatic interactions with cells very weak, but polymers or nanoparticles
with many cationic sites can bind stably to cells via multivalent electrostatic interactions
(Fig. 1h). To this end, Wilson et al. functionalized PEG polymer with cationic poly-L-lysine
for electrostatic adsorption onto the surface of pancreatic islets[38]. Beyond their
applications in organ transplantation as a physical barrier between allograft tissue and the
host immune system, functionalized multilayer films coated on cells have also shown great
promise for protecting damaged blood vessels from platelet adhesion and vessel
stenosis[106]. Furthermore, by alternate layering of cells and polyelectrolyte films, multilayer
cellular constructs can be engineered which mimic the 3-D structure and cellular
composition of functional organs[107]. Presumably due to a combination of van der Waals,
electrostatic, hydrogen bonding, and hydrophobic interactions, certain nanoparticle
formulations can also nonspecifically adsorb to cell membranes[108]. As further discussed
below, such attachment to a cellular chaperone can drastically reduce systemic clearance of
nanocarriers[108,109].
Interaction of a ligand with a receptor naturally present on the cell surface
Physiologically-expressed transmembrane receptors are tempting targets to conjugate
biomaterials functionalized with their respective ligands to cells. However, receptor-ligand
interactions are transient in nature, determined by intrinsic binding and dissociation
kinetics[110], which restricts their utility for stable coupling of material to cell surfaces[111].
However, multivalent binding of ligand-decorated materials with cell surface receptors can
lead to stable cell surface binding. For example, work by Swiston et al. demonstrated that
the multivalent interaction between cell surface CD44 receptors and the “flat” face of
polyelectrolyte multilayer disks (with diameters of 5–10 μm but thicknesses of a few
hundred nm) displaying hyaluronic acid (the natural ligand of CD44) is strong enough to
anchor HA-coated multilayer thin films to T cells[65] (Fig. 2a). To tether single-walled
carbon nanotubes (CNTs) to cell surface glycoprotein ligands, Bertozzi and coworkers first
coated CNTs with a biopolymer designed to mimic cell surface glycoproteins. Using a
hexavalent lectin (polysaccharide-binding protein) as a crosslinker, surface-modified CNTs
were efficiently attached to live cells[112]. The unique hollow monolithic structure
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comprising an outer and inner core, which can be independently functionalized or loaded
with therapeutics[113] are especially valuable features of CNTs as cell surface engineering
tools. More recently, this approach was extended to surface-functionalize cells with less
cytotoxic boron nitride nanotubes[114]. In principle, any ligand-, aptamer-, or antibody-
targeted compound or nanoparticle can site-specifically attach to cell surfaces. However cell
surface engineering is predicated on retaining the material at the cell surface, and many
targeting agents trigger internalization of their receptor on binding, which will preclude
stable surface modification (discussed further below).
The role of nanomaterials in achieving stable cell surface modification
The approaches reviewed above for linking exogenous molecules, particles, and polymer
films to cells do not necessarily address the larger issue of stable cell surface modification.
In general, exogenous molecules linked monovalently to cell surface proteins/lipids/
polysaccharides will be retained on the cell surface only as long as the membrane molecule
to which they are bound, which may range from minutes to hours. In fact, the rapid and
efficient internalization of ligand-, antibody-, or aptamer-conjugated drugs or nanoparticles
following binding to target proteins on the cell surface is a critical determinant of efficacy
for many targeted drug delivery strategies[115,116]. Notably, multivalent crosslinking of
receptors by ligand-functionalized nanoparticles binding to the cell surface does not prevent
internalization in many diverse systems and cell types[117,118]. However, studies aiming to
create long-lived cell surface modifications using micro- and nano-structured materials have
begun to identify some strategies to physically or chemically induce long-lived cell surface
association of exogenous materials.
Engineering stable cell surface association via engineered particle shape
One emerging strategy to regulate the internalization of synthetic materials following cell
contact is via the physical shape of the exogenous material: In general, materials with large
aspect ratios, such as disc- or worm-like shapes, are internalized at significantly decreased
rates compared to spherical material[119,120]. In line with these observations, Swiston and
co-workers reported that micrometer-diameter polymer patches with nanoscale thickness
stably attached to and remain on the surface of T cells[65] and even phagocytic B
lymphocytes[121] for several days in cell culture (Fig. 2a). In a related study, Cheng et al.
demonstrated that mesenchymal stem cells, which typically internalize nanostructures within
minutes or hours[122], retain linked nanoparticulate patches on the cell surface for up to 2
days[72] (Fig. 2b). Notably, to understand the fate of nanomaterials following association
with the cell surface, physical geometry and the mechanisms of cell binding must be
considered together to understand the fate of exogenous materials binding to the cell surface,
as highlighted by Jiang and colleagues[123]: By synthesizing nanoparticles of various sizes
coated with high densities of growth factor receptor-binding antibodies, this study
demonstrated that cells most efficiently internalized nanocarriers within the 25–50 nm size
range. In contrast, larger 70 nm-diam. particles bound to cells but mostly remained localized
on the cell surface over a period of hours. Given that the cellular uptake of nanocarriers may
depend on receptor-mediated wrapping of the cell membrane around the particle[124], the
authors reasoned that larger nanostructures with a high density of receptor binding sites
occupy all the receptors available in the local vicinity of the membrane on a single face of
the particle. This reduction of receptors in the immediate neighborhood of the adhesion
region then limits additional ligand-receptor interactions, which would be required to
completely coat nanoparticles and trigger endocytic uptake.
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Mechanisms of cell association control cell surface stability of exogenous materials
In addition to size and geometry aspects, the mechanism of cell attachment plays a key role
in the stability of cell surface modifications; certain strategies for the attachment of
nanomaterials or molecules to cell surfaces lead to rapid internalization, while others appear
capable of stably modifying the cell surface (Fig. 2a–c). As stated above, turnover rates of
macromolecules which are exogenously inserted into the membrane of live cells, such as
biomimetic receptors, glycopolymers, surface glycans or GPI-anchored proteins, tend to
mirror those of natural membrane-associated biomolecules[34,35,101]. Rapid membrane
dynamics, however, bear the risk of premature loss of therapeutic membrane-embedded
macromolecules owing to endosomal internalization (Fig. 2d). A positive surface charge of
biomaterials in contact with inherently negatively charged cell membranes can cause local
membrane depolarization and also trigger subsequent intracellular uptake[125,126]. To
immobilize and maintain nanostructures on the outer membrane of cells for days, even
following cell proliferation, covalent linkage strategies to reactive groups inherently present
on their exterior cell surface have proven most promising. For example, conjugation of lipid
or polymer nanoparticles in the 100–300 nm diam. size range to free thiols on the surface of
primary T cells or hematopoietic stem cells led to stable cell surface localization of these
nanomaterials, even during/after cell division (Fig. 2c)[36]. Importantly, coupling of up to
~100 particles/cell was nontoxic and was not found to affect key cellular functions, such as
in vivo migration, proliferation or cell fate. The mechanistic underpinnings of this durable
surface-coupling of nanocarriers to cells remains to be determined. In agreement with
previous work (Fig. 2e)[118], our group has observed some degree of internalization of
nanoparticles coated with antibodies to CD3 or CD8 by primary T lymphocytes as a result of
receptor-induced endocytosis (Fig. 2f and unpublished results). These results suggest that it
is not size, shape or surface charge of the nanoparticles that explains the prolonged surface
retention seen in our adoptive T-cell therapy studies, but rather the maleimide-thiol coupling
strategy itself. Therefore, a key to understanding and further optimizing this promising
surface modification approach will be identification of the surface proteins maleimide-
functionalized nanocarriers commonly bind, and, ultimately, to determine whether the
covalent coupling of nanomaterial to surface proteins delays or even prevents inherent
protein turnover and membrane recycling.
Key therapeutic gains achieved by cell surface engineering
Retargeting systemic cell homing
Direct injection of therapeutic cell products into target tissue sites is practicable only for a
limited number of applications, such as intracoronary infusions of myoblasts into the
damaged heart muscle, pancreatic beta islets transplants through the portal vein into the liver
or subcutaneous injections of cellular vaccines[9,10,13]. For most cellular therapies, which
target systemic multifocal sites of injured, inflamed or cancerous tissue, intravenous delivery
is the preferred mode of cell administration. Hence, efficient homing of donor cells to the
tissue or organ of intended action is crucial to the therapeutic success.
Given that only a subset of intravenously injected cells may engraft in the tissue of interest
due to the absence of the key homing receptors on infused cells[127], the lack of sufficient
chemoattractants, or the presence of suppressive stromal barriers at target locations[128],
methods of improving therapeutic cell trafficking are a high priority. A wide variety of
simple yet versatile cell engineering methodologies have been reported to program the in
vivo trafficking of systemically delivered cells. Sackstein et al. demonstrated that
mesenchymal stem cells, which inherently display limited bone marrow tropism, more
efficiently engraft to this site when enzymatically surface-engineered ex-vivo with an E-
selectin binding motif that is responsible for bone marrow-homing of hematopoietic stem
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cells[35,80]. This ex vivo glycan engineering strategy was also applied to enhance the
engraftment of human umbilical cord blood cells[129]. Traditionally, cord blood has been the
standard source of cells for hematopoietic cell transplantation in pediatric patients only,
owing to the limited number of stem cells available in a typical cord blood unit[130]. By
enzymatically optimizing the bone marrow tropism of infused cord blood cells and thereby
significantly reducing the required number of stem cells, adult recipients could potentially
be transplanted using cord blood.
Beyond rationally designing cell surface glycoforms, cell homing responses can be induced
by functionalizing cell membranes with recombinant targeting ligands. As an alternative to
directing regenerative cells to tissue antigens exposed within injury sites, vascular
addressins, which are ubiquitously displayed on inflamed endothelial surfaces to mediate
rapid deceleration of circulating immune cells, can be directly targeted. To promote
attachment to activated endothelium, Dennis and coworkers coated mesenchymal stem cells
with antibodies to ICAM-1 through membrane-inserted palmitated protein G as docking
points[97] (e.g., method of Fig. 1d). In a related study, the Karp group immobilized the
carbohydrate molecule Sialyl Lewis X (SLeX) as high-affinity P-selectin ligand on the
surface of mesenchymal stem cells using biotin-streptavidin bridges[31]. Like leukocytes
adhering to the luminal surface of inflamed vasculature to subsequently migrate into
underlying damaged tissue, SLeX surface-engineered mesenchymal stem cells decelerate
and roll on P-selectin-coated substrates.
Providing transplanted cells with autocrine sources of growth factors
Once therapeutic cytoreagents reach their desired location, cell viability, function and
expansion critically rely on a sustained supply of oxygen, nutrients and growth factors.
Access to these factors for transplanted cells can be limited as a result of competition with
endogenous host cells[131] or due to a hostile microenvironment characterized by tissue
necrosis, hypoxia or acidosis[132]. In addition, adoptively transferred tumor-targeted T
lymphocytes need to overcome an immune-evasive tumor microenvironment with
suppressive molecules and inhibitory cells[133]. To promote in vivo longevity and function of
cell transplants, adjuvant growth factors, such as cytokines[24] antibodies[134,135] or small
molecule drugs[136,137] are administered intravenously. However, systemic adjuvant
injections generally do not selectively target the transplanted cell population, and high
systemic drug levels need to be maintained through repeated bolus injections. This often
results in dose-limiting toxicities, and ultimately precludes the clinical use of many
potentially potent adjuvants drugs[23,138]. To focus adjuvant drug action on the transferred
cell, thereby minimizing systemic side effects, nanoparticles loaded with growth factors can
be directly conjugated onto the surface of donor cells (Fig. 3)[36]. In this strategy, supporting
drug molecules are slowly released from cell-bound nanoparticles and primarily recaptured
by particle-carrying cells in autocrine signaling loops. Using this approach to enhance the
survival and function of anti-tumor T-cells, the cytokines interleukin (IL)-15 and IL-21 were
attached to T-cells at minimal doses that had no therapeutic effect when given systemically.
When these same cytokine doses were encapsulated in lipid nanoparticles (which released
the drugs over the course of ~1 week) and directly attached to the donor T-cells, massive in
vivo T cell expansion was induced, leading to complete clearance of systemic melanoma
tumor burdens. This simple approach for donor cell modification also enhanced the
engraftment and repopulation kinetics of hematopoietic stem cells, by locally releasing a
glycogen synthase kinase-3β inhibitor (known to enhance HSC expansion) from cell
surface-linked nanoparticles carrying minute quantities of drug[36]. While the clinical
introduction of this HSC surface engineering strategy is still distant, the key benefits of this
technology compared to conventional HSC transplant regimens are highly appealing. As
part of the ongoing clinical effort to enhance HSC proliferation and in vivo homing, a
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growing number of small molecule drugs, such as 16,16-dimethyl Prostaglandin E2
(FT1050), have entered phase 1 testing in human subjects[20,139]. However, to avert possible
systemic toxicities in response to intravenous bolus injections, stem cell modulators need to
be administered ex vivo prior to infusion. By slowly releasing the HSC-stimulating agent
from cell surface-coupled nanoparticles instead, cells could be infused directly into the
recipient without overnight in vitro culture. Furthermore, adjuvant nanoparticles stably
conjugated to HSCs follow the characteristic in vivo migration patterns of their cellular
vehicles and can promote early stages of engraftment through sustained in vivo drug release.
Whether nanoparticles loaded with small molecule drugs that freely cross cell membranes or
that target cytoplasmic receptors need to be surface-displayed to exhibit their optimal
adjuvant effects in vivo is subject to ongoing experiments. Recent in vitro studies by Riley
and colleagues demonstrated that microparticles loaded with the differentiation factor
Dexamethasone still efficiently induced osteoblastic differentiation following their uptake
by human mesenchymal stem cells[140]. Interestingly, in addition to triggering intracrine
differentiation pathways, internalized drug particles also controlled the cell fate of
unmodified bystander cells through paracrine-like signaling.
Targeting drugs to therapeutically relevant tissue sites using cellular carriers
Following conventional drug administration via oral ingestion or intravenous injection,
therapeutic agents are distributed throughout the body through the systemic circulation, with
only a small fraction of the injected dose actually reaching the intended target cells[141]. In
addition, the temporal window over which drugs are present in the tissues at therapeutically
meaningful doses can be extremely short, causing a need for frequent repeat dosing. To
overcome these limitations, drug-loaded synthetic nanocarriers are being implemented as a
means to deliver therapeutic agents over sustained periods in the bloodstream or to target
high concentrations of drug cargos to relevant tissue sites, thus reducing drug toxicity while
increasing treatment efficacy[142]. These approaches are rapidly progressing in the field of
cancer therapy, where passive accumulation of nanocarriers at tumor sites via the enhanced
permeation and retention effect[143] (highly disorganized, leaky tumor vasculature in
combination with compromised lymphatic drainage) is often observed. Nonetheless, only a
small percentage (typically, a few percent) of the total injected dose is delivered into the
tumor microenvironment due to rapid particle clearance by immune cells in the liver and the
spleen (collectively referred to as the reticuloendothelial system, or RES)[144]. Particle
clearance from the blood also limits the time window over which nanoparticle carriers can
provide systemically-available drug. To further improve on these problems, cell surface
engineering has been applied to therapeutic drug delivery.
Inspired by the observation that some pathogens efficiently evade immune clearance by
attaching themselves to the surface of red blood cells (RBCs)[145,146], protocols were
developed to test the hypothesis that RBC-bound drugs or drug carrier nanoparticles would
be shielded from rapid scavenging by the RES following systemic administration. Initially,
autologous erythrocytes were the prime candidates for use as drug delivery vehicles because
of their abundance (~5.4 million cells/mm3 blood), their considerably uniform size and
shape, and their long life span in circulation (110–120 days)[147]. Murciano et al.
successfully coupled tissue type-plasminogen activator (tPA), which is used clinically to
dissolve arterial thrombi, to the surface of isolated erythrocytes, to extend the inherently
short circulation half-life of this fibrinolytic drug[69]. Following intravenous injection, tPA-
decorated RBCs could durably protect animals from induced thrombi, whereas an equal dose
of soluble tPA had no prophylactic effect. Despite significantly increasing the circulation
lifetime of a therapeutic agent, the methodology of anchoring drugs to the surface of cellular
carriers is inherently limited to agents that are effective while still attached to the cell
membrane. To combine the benefits of synthetic nanoparticles as slow-release depots of a
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wide range of therapeutic cargos with the use of cellular carriers, which might prevent
premature clearance of the particles from the blood, cell-nanoparticle hybrid vectors have
been developed. In a proof of concept study, Chambers and colleagues reported that the non-
covalent attachment of polystyrene beads as large as 450 nm to the surface of RBCs
dramatically increased their circulation time compared to particles injected freely into the
blood[109]. These highlighted studies only exemplify a multitude of therapeutic applications
of erythrocytes as cellular carriers of biopharmaceuticals explored through more than five-
decades of intensive development[148,149]. However, the implementation of erythrocytes as
widespread drug delivery systems in clinical therapies is hindered by major drawbacks.
Most lipophilic drugs with limited water solubility can only be entrapped into red blood
cells at concentrations below therapeutic levels, and exhibit a burst release of the loaded
drug during early cell preparation stages or in vitro cell storage[150,151]. Moreover, most
methods developed to chemically modify red blood cells induce irreversible destructive
changes in the cell membrane. This predisposes carrier erythrocytes to premature clearance
from the circulation by the reticulo-endothelial system in the liver or spleen[152]. Finally,
compared to other cellular blood components, such as monocytes or lymphocytes,
erythrocytes lack inherent migratory properties, which preclude their use for active drug
targeting to defined tissue sites. Thus, despite much effort, clinical products based on
engineered red blood cells have not yet translated to the clinic.
In parallel to the pursuit of red blood cell engineering, recent advances in our understanding
of in vivo migration patterns of immune or stem cells to inflamed, hypoxic or cancerous
tissue combined with technical advances of cell isolation and in vitro expansion have
expanded the field of cellular drug carriers to cell types beyond erythrocytes. For instance,
the inherent ability of monocytes/macrophages and mesenchymal stem cells to migrate to
hypoxic, necrotic, and inflamed tissue[127], makes them ideal candidates as cellular carriers
of cancer therapeutics or tumor imaging agents[153]. Most commonly, isolated monocytes or
mesenchymal stem cells are “fed” and loaded in vitro with nanocarriers, which contain
membrane-permeable therapeutics[40,154]. Following their systemic injection, tumors
actively recruit these cells, which subsequently release their toxic payload in a highly
controlled and directed manner. Although the intracellular delivery strategy of therapeutic
nanoparticles may seem obvious for phagocytic carrier cells, coupling the therapeutic cargo
to the cell surface could reduce the toxicity of the therapeutic agent on the carrier cells. To
this end, Chen and colleagues chemically anchored nanoparticle “patches” to the membrane
of mesenchymal stem cells without compromising key intrinsic cell functions[72] (Fig. 2b).
Using Schiff base linkage chemistry, Holden et al. demonstrated durable coupling of
PEGylated dendrimers to the surface of macrophages[78], which sets the stage for the future
development of macrophage-nanoparticle hybrid vectors as tumoritropic drug delivery
vehicles.
Effector T-cells have also been tested as chaperones of surface-attached therapeutic cargo,
motivated by their the clinical track record of adoptive T-cell therapy in cancer and the ease
in harvesting, genetically modifying and expanding these cells to clinical scale[155]. Further,
T cells can efficiently infiltrate systemic tumor lesions across endothelial and stromal
barriers[156]. Based on the unexpected finding that viral particles adsorbed to the membrane
of T lymphocytes can be released and taken up by tumor cells in vivo at tumor site[157],
several groups have successfully used adoptively-transferred tumor antigen-specific T cells
to carry oncolytic viruses to tumor deposits[39,158,159]. By “hitchhiking” on tumoritropic
cells, therapeutic viral particles aggregate in poorly accessible compartments and lyse tumor
cells in synergy with their cytotoxic carrier T-cells. Extension of this approach to delivery of
synthetic drug-loaded nanoparticles will be an attractive goal, since many relevant cancer
diagnostics and therapeutics cannot be delivered by viruses, such as small molecule drugs,
antibody-drug-conjugates, aptamers, or magnetic imaging agents[160–162]. In vivo
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biodistribution assays in tumor-bearing animals have confirmed that T-cell-coupled
nanoparticles with sizes of 200–300 nm diam. follow the inherent migration pattern of their
cellular vehicles and efficiently accumulate at tumor sites, while the same particles injected
systemically were rapidly scavenged by the liver and the spleen and showed negligible
tumor uptake[36]. This result highlights a key area for further research: Accumulation of
freely injected nanoparticles in tumor sites is highly dependent on precise tuning of particle
size, with an optimum near 100 nm diam. In contrast, the same size limitations do not apply
to cell-carried nanomaterials, and defining the upper limit for particle sizes that are
efficiently trafficked into tissues by chaperone cells will be an important parameter to
define, since a modest change in particle size will have a tremendous impact on the payload
of drug carried per particle. The profoundly altered biodistribution of cell-nanoparticles
hybrid vectors and potential to utilize particles with sizes outside the narrow range optimal
for “free” particle tumor accumulation strongly motivates the continued translational
development of such “pharmacytes” as actively targeting cell products, which deliver
therapeutic or diagnostic agents to desired anatomical compartments[163,164].
Tracking adoptively transferred cells in vivo
To optimally evaluate the efficacy of cell-based therapies in clinical studies it is fundamental
to monitor cell homing to target tissue and in vivo persistence by noninvasive cell imaging.
Currently, two distinct technologies are employed to track cell location in patients: (1)
Loading cells ex vivo with probes, including radioisotope-labeled chemicals for Positron
Emission Tomography (PET) imaging[165] or contrast agents for Magnetic Resonance
Imaging (MRI)[166], and (2) genetically engineering cells ex vivo to constitutively express a
reporter gene, such as the widely used PET reporter gene Herpes Simplex Virus 1 thymidine
kinase (HSV-tk)[167].
The approach of ex vivo cell labeling is primarily designed to determine the short-term fate
of transplanted cells, given that tagged cells dilute out the imaging probe with every cell
division following their adoptive transfer. Unfortunately, most imaging agents developed to
enhance the resolution in MRI, such as superparamagnetic iron oxide nanoparticles
(SPION), are known to induce cellular stress and perturb cell functionalities and gene
expression once inside the cytosol[168]. This raises many safety concerns, including the risk
of aberrant in vivo cell responses, the risk of induced mutagenesis or the lack of therapeutic
potency of a cell product due to premature apoptosis. On the other hand, genetically tagging
therapeutic cells, while allowing for long-term longitudinal cell imaging, permanently alters
their genetic composition and adds significant costs and regulatory roadblocks[169].
In the light of these shortcomings, the direct coupling of imaging agents or nanoparticulate
carrier systems loaded with imaging reagents to the external membrane of cells prior to
infusion could provide significant advantages for in vivo cell imaging. Based on the wealth
of available nanoparticle formulations and protocols to chemically modify cell surfaces (Fig.
1) the range of imaging tracers that can be linked to therapeutic cells without compromising
cell functions extends far beyond the abovementioned magnetic contrast agents. New cell
surface engineering strategies could encompass (1) coupling high-affinity antibody
fragments, which are widely used reagents to sequester radionucleotides in pretarget
radioimmunotherapy[170], to the surface of cells (2) tethering synthetic nanoparticles, which
are loaded with recombinant reporter enzymes, such as HSV-tk for PET imaging, or (3)
surface-labeling cells with colloidal quantum dots[171] for near-infrared cell imaging. Since
many cell types explored therapeutically in clinic, such as myoblasts, neuronal stem cells, or
pancreatic islet beta-cells exhibit low in vivo proliferative rates[172], cell surface coupling
strategies are not restricted to monitoring the short-term fate of transplanted cells.
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Future Directions
Currently, over 500 companies are involved in the development and commercialization of
cell-based products[173] to treat a range of diseases, including tissue degeneration, chronic
inflammation, autoimmunity, genetic disorders, cancer, and infections. In retrospect, cell
therapy has undergone a tremendous metamorphosis from a discipline traditionally defined
by blood transfusions and bone marrow transplantations into a nascent healthcare industry.
The strong clinical presence of an expanding array of cell therapy products has also
catalyzed the field of cell engineering with the goal of maximizing the therapeutic
performance of cytoreagents in patients. In this review we have highlighted strategies
developed to rationally design the microarchitecture of cell surfaces with synthetic
nanomaterials. Cell products are not replenishable “off-the-shelf” reagents, but rather live
therapeutics, that are costly to harvest, purify and expand. With this in mind, most cell
bioengineering work discussed in this review has been geared towards minimizing cell
damage or loss by avoiding non-physiological cell culture conditions or excessive cell
handling. However, to successfully transition cell surface bioengineering technologies into
clinically viable tools, future research efforts will be needed to optimize additional
parameters.
New materials for cell surface engineering
The advent of advanced biomaterial discovery tools, such as combinatorial synthesis, high-
throughput experimentation or computational modeling[174], has led to the development of a
substantial number of next-generation biomaterials with superior biocompatibility and
functionality. These compounds hold the promise to further diversify and accelerate the
clinical implementation of cell surface bioengineering approaches.
One emerging class of materials are DNA/RNA molecules as building units of self-
assembling secondary and tertiary structures[175,176]. Branched oligonucleotide sequences in
combination with “sticky” ends create a powerful molecular assembly kit to rationally
modify surfaces of therapeutic cells. Francis and co-workers have shown proof of concept
that synthetic DNA strands can be hybridized to the surface plasma membrane of living
cells[67]. Since aptamers, which are oligonucleotide molecules that bind to specific targets,
have emerged as a class of molecules that rival antibodies in both therapeutic and diagnostic
applications[161], their use as cell targeting ligands in the clinic may provide major
advantages compared to conventional protein ligands. In contrast to recombinant proteins,
aptamers are comparably compact, they can be rapidly developed in vitro against virtually
any class of target molecules, including protein antigen, fatty acids, carbohydrates and even
synthetic compounds. Moreover, aptamers can be engineered to avoid in vivo
immunogenicity[177]. Another novel technology with tantalizing therapeutic potential for
cell engineering is the field of bio-responsive or bio-interactive materials[178–181]. This
methodology exploits biological events or stimuli, such as cell-secreted enzymes, pH,
temperature, photon flux or ligand binding events, as triggers to induce macroscopic
transitions in materials. As a result, “smart” or “sensing” compounds can be designed to
perform sophisticated functions. In the context of cell surface engineering one could
envisage cellular “Trojan horse vehicles” tuned to release their drug payload only once
reaching tumor targets with acidic pH environments. Such on-demand drug release would
further minimize premature metabolism and excessive background levels of drugs with high
toxicity. Disease-specific enzymes could also trigger the display of cell membrane-inserted
bioactive ligands to instruct cell behavior on-site only without off-target stimulation of
irrelevant bystander cells while circulating in the blood stream.
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Regulatory issues and cost-effective scale-up
Personalized cell therapies have high production costs (currently, ~$25,000 per treatment for
adoptive T cell therapy[182]) based on labor-intensive cell harvesting, large-scale cell
expansion and the requirement for extensively trained personnel and specialized
manufacturing facilities. Due to high research and development costs, commercialized
cytoreagents are even more costly, exemplified most recently by Dendreon’s $93,000/
patient autologous dendritic cell cancer vaccine Provenge® [183]. The large-scale synthesis
of therapeutic nanomaterials with GMP- (good manufacturing practices) compliant reagents,
especially with recombinant proteins involved, will significantly add to the already high
price tag of established cellular therapies.
From a regulatory perspective, the most likely scenario for initial commercialization of cell
engineering would be the development of drug-loaded nanomaterials that are themselves
off-the-shelf reagents that could be combined with cells just before transfer into patients.
This approach would allow GMP-compliant processing and characterization of the materials
(e.g., cell-binding nanoparticles) to be independently established and “plugged in” to
existing clinical cell therapy protocols such as MSC, islet cell, or stem cell transplants. In
this setting, many of the methodologies employed for establishing the safety,
pharmacokinetics, and efficacy of existing clinical nanomaterials (e.g., chemotherapy-
loaded liposomes) might be applied. Clearly, drug-carrying nanomaterials designed for cell
conjugation would face a lower barrier to approval if initially based on existing, clinically-
used drugs. Modification of commercial cell therapies a la Provenge® would pose additional
hurdles for FDA approval.
Notwithstanding these technical and regulatory issues, cellular engineering tools become
economically justified if highly effective. Given that a majority of cell therapies are
currently non-curative and fall short of desired clinical efficacy[184], a one-time treatment
with a cell product engineered with curative properties is most cost effective since it cuts
down on costly palliative care to manage disease relapse. Furthermore, the adoptive transfer
of a significantly reduced number of cells demonstrating superior clinical efficacy,
compared to the infusion of large quantities of short-lived/low potency cells will reduce the
cost and complexity of cell manufacturing. It is likely that the most attractive setting for
these concepts in the clinic will be delivery of highly potent yet inexpensive small molecule
compounds, which might replace expensive adjuvant drug treatments and produce dramatic
changes in the efficacy of cell therapy while avoiding substantial increased costs to these
therapies.
In vivo cell surface bioengineering?
In an ideal scenario one could envision directly engineering surface properties of defined
therapeutic cell populations in their physiological environment within the patient without the
need for ex vivo cell isolation and expansion. Besides being costly and laborious, large-scale
cell expansion often renders cells functionally exhausted and significantly reduces their
subsequent proliferative potential[185]. It would, therefore, be highly desirable to develop in
vivo cell bioengineering methodologies that expand, re-target or functionally enhance
endogenous pools of pathophysiologically relevant cell types, such as mesenchymal stem
cells, hematopoietic stem cells or tumor antigen-specific T lymphocytes. As a step in this
direction, the Fahmy group has recently developed tolerogenic nanoparticles targeted to
specifically bind to CD4+ T lymphocyte populations via surface-attached anti-CD4
antibodies. A brief mixing of these targeted particles with unpurified splenocytes ex vivo led
to CD4+ T-cell labeling with the drug-loaded particles, and on infusion into animals, these
cells differentiated into immune-suppressive regulatory CD4+ T lymphocytes[186]. Fahmy
and Saltzman have also shown that dendrimers carrying doxorubicin can be targeted onto
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antigen-specific T-cells directly in vivo by injecting dendrimers carrying peptide-MHC
ligands (which bind to specific T cell receptors of their target cells[187]). Blood-circulating
cells such as lymphocytes are the ideal targets to attempt in situ cell engineering, as these
cells are in theory fully accessible to nanomaterials injected intravenously and the
opportunity exists for cell binding to scavenging by the RES. Beyond nanoparticulate
biomaterial, recent studies by Mooney and colleagues demonstrate that bioplymer scaffolds
can mimic three-dimensional immune cell niches and in situ instruct endogenous immune
cells to efficiently target tumors[188]. Following subcutaneous implantation, this biomaterial
vaccine platform, termed Cellarium™, slowly releases GM-CSF and the danger signal CpG-
oligodeoxynucleotide, which in combination attract and mature circulating dendritic cells
into the porous scaffold. Subsequently, dendritic cells take up tumor antigen incorporated
into the matrix, mature and emigrate into regional lymph nodes where they can prime tumor
antigen specific CD8 T lymphocytes. Although important questions pertaining to the clinical
value of this vaccine device in cancer patients with tumor-induced dendritic cell dysfunction
and immune-suppressive dendritic cell populations await detailed clinic testing, Cellarium™
could provide major therapeutic benefits compared to conventional cancer vaccines.
As proof-of-principle that in situ cell surface engineering protocols can be developed to
chemically modify selective cell membrane biomolecules in a living organism, Bertozzi and
colleagues employed Copper-free click chemistry to metabolically label surface glycans in
live mice[189,190]. While encouraging, these in vivo cell engineering efforts warrant further
development and refinement to safely perform chemical reactions in living subjects. Key
tasks in this regard are the identification and validation of high-affinity and high-specificity
agents which target only defined cell populations in vivo, thereby preventing potentially
harmful side effects.
Despite the challenges, ample opportunities for the further advancement of cell surface
bioengineering as a clinical tool to endow cells with enhanced therapeutic properties lie
ahead of us. Many of the robust methodologies described in this review are primed for
translation across widespread clinical indications in the near future, while others are still in
their infancy and face significant biological or safety uncertainties. To avoid being stalled in
preclinical studies cell engineering strategies will need to remain focused on therapeutic
efficacy, but also take into consideration factors such as labor intensity and cost which will
govern the clinical availability and ultimately the commercial success of cell therapy
products.
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cell therapy, Dr. Stephan pioneered a methodology to enhance the persistence and
functionality of adoptively transferred cells, which is based on the stable chemical
conjugation of drug-loaded nanoparticles to the surfaces of cell products just prior to
reinfusion. His work was recognized with the 2010 “Future Leader in Translational
Medicine Award” by the American Academy for Cancer Research (AACR) and a NIH Ruth
L. Kirschstein Research National Research Service Award.
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Harvard. His research is focused on the application of engineering tools to problems in
cellular immunology and the development of new materials for vaccine and drug delivery.
These efforts largely focus on cellular immunology and vaccine development for HIV and
immunotherapy of cancer.
Stephan and Irvine Page 25
Nano Today. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. The cell surface bioengineering tool box
Schematic of key bioengineering methodologies to therapeutically modify the surface of live
mammalian cells. (a) Direct conjugation of therapeutic materials (TM) functionalized with
reactive groups which covalently bond to amine (−NH2) or thiol (−SH) groups, intrinsic to
cell membrane proteins. (b) Covalent attachment of biotin anchors to membrane proteins by
reacting N-Hydroxysuccinimide (NHS)-activated biotin with primary amine groups in
membrane proteins, followed by streptavidin-biotin linkage of TM. (c) Exogenous insertion
of recombinant GPI-anchored proteins into the outer membrane leaflet (d) Exogenous
insertion of palmitate-conjugated protein A or G into the cell membrane to subsequently
immobilize antibodies or recombinant Fcγ-fusion proteins. (e) Anchoring ligand-
functionalized TM to membrane receptors naturally present on the cell surface. (f) Metabolic
labeling of surface glycans by the biosynthetic introduction of unnatural sugars containing
unique functional groups, which serve as reactive sites for the attachment of TM. (g)
Targeting TM site-specifically to surface proteins genetically fused to the BirA biotinylation
enzyme acceptor peptide (AP) sequence. (h) Nonspecific electrostatic adsorption of cationic
TM to the negatively charged cell membrane.
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Figure 2. Durable surface coupling (a–c) versus rapid internalization (d–f) of therapeutic
material following different cell surface engineering strategies. (a) Attachment of micrometer
scale polymer layers to cell membranes
Schematic of a multilayer hyaluronic acid-functionalized polymer patch attached to the
surface of a T lymphocyte through intrinsic CD44 membrane receptors (left panel).
Confocal microscopy image of a patch- (green fluorescence) functionalized T-cell. Scale
bar, 10 μm (right panel). Adapted with permission from Swiston et al. (2008). (b) Tethering
nanostructures to biotinylated cell membrane proteins. Schematic illustration of
NeutrAvidin-coated nanoparticulate patches anchored onto a biotinylated plasma membrane
(left panel). Scanning electron microscopy images of nanoparticle cluster on a human
mesenchymal stem cell membrane (right panel). Adapted with permission from Cheng et al.
(2010). (c) Covalent coupling maleimide-functionlized nanocarriers to free thiol groups
on membrane proteins. Schematic of maleimide-based conjugation of synthetic lipid-
coated nanoparticles (NP) to cell surface thiols and subsequent quenching of residual
maleimide headgroups on nanoparticles by in situ conjugation to thiol-terminated
polyethylene glycol (PEGylation) (left panel). Confocal microscopy images of CD8+
effector T cells immediately after conjugation with fluorescent multilamellar lipid
nanoparticles and after 4-d in vitro T cell expansion (right panel). Scale bar, 2 μm. Adapted
with permission from Stephan et al. (2010). (d) Incorporation of bioactive synthetic
glycopolymers into cellular membranes. Schematic of synthetic mucin-mimic
glycopolymers exogenously inserted into the cellular membrane through hydrophobic
anchors (left panel). Fluorescent microscopy image of ldlD CHO cells incubated for 1 h with
synthetic glycopolymer (green). Nuclei are stained with Hoechst 33342 in blue (right panel).
Scale bar, 10 μm. Colocalization of glycopolymers and early endosomes was confirmed.
Adapted with permission from Rabuka et al. (2008). (e) Selective targeting of antibody-
conjugated nanoparticles to T lymphocyte T cell receptors. Schematic illustration of an
anti-CD3 antibody-functionalized nanoparticle (NP) coupled to the T cell receptor CD3
complex. To immobilize biotinylated anti-CD3 antibodies nanoparticles were modified with
NeutrAvidin (left panel). Confocal microscopy image of CD3+ Jurkat cells cultured in the
presence of FITC-conjugated anti-CD3-NP for 4 h. To visualize cellular membranes cells
were counterstained with Alexa fluor 594-conjugated concanavalin A (right panel). Scale
bar, 8 μm. Adapted with permission from Balthasar et al. (2005). (f) Tethering particulate
carriers to CD8 antigen on human effector T lymphocytes. Illustration of an antibody-
nanoparticle (NP) conjugate targeted to the CD8 antigen on the surface of a human CD8+ T
cell (left panel). Confocal microscopy of a human CD8+ effector T lymphocyte incubated
with anti-CD8-decorated fluorescent nanoparticles for 45 minutes (right panel). Scale bar, 3
μm (M.T. Stephan, unpublished data).
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Figure 3. Stable chemical conjugation of adjuvant-loaded nanoparticles (NP) to the surfaces of
transplanted cells permits pseudo-autocrine self-stimulation while limiting potentially harmful
paracrine stimulation of bystander cells
(a) Schematic of adoptively transferred therapeutic cells in the presence of recipient
bystander cells. To provide sustained autocrine stimulation, adjuvant growth factor-loaded
nanocarriers are conjugated to the surfaces of donor cells just prior to cell infusion. A
magnified view of nanoparticle-modified versus unmodified surface membranes, which
further illustrates autocrine versus paracrine cell stimulation, is shown in the lower inset. (b)
T cell-linked adjuvant NPs activate primarily their own cellular carrier with minimal
stimulation of bystander cells. B16F10-OVA lung tumor-bearing mice were treated by i.v.
co-transfer of luciferase-expressing pmel-1 reporter T-cells together with luciferase-negative
OT-1 T cells. In the “no adjuvant” group mice received unmodified T lymphocytes. To
quantify “paracrine stimulation” of cell-conjugated adjuvant nanoparticles, luciferase-
expressing pmel-1 T cells were co-transferred with luciferase-negative OT-1 T cells
decorated with interleukin 15/21-loaded nanoparticles prior to adoptive transfer. “Autocrine
stimulation” of surface-tethered adjuvant nanoparticles was determined by adoptive transfer
of luciferase-transgenic pmel-1 T cells surface-modified with adjuvant releasing
nanoparticles in the presence of unmodified OT-1 T cells. Shown are representative in vivo
bioluminescent images. Respective whole body bioluminescent pmel-1 T cell photon counts,
quantified every 2 d during initial T cell expansion, are shown in (c). The much greater
pmel-1 T-cell expansion seen in the “autocrine stimulation” case shows that most of the
drug released from cell-bound particles acts on the carrier cell itself, rather than bystander
cells in the local microenvironment. Adapted with permission from Stephan et al. (2010).
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